Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures

Maissaa Janbain, Diane J. Nugent, Jerry S Powell, Jean St-Louis, Virginia B. Frame, Cindy A. Leissinger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background Patients with congenital Factor XIII (FXIII) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of FXIII concentrates before and during surgery are lacking. The objective of this study was to report the use of plasma-derived FXIII concentrate (Corifact in the United States; Fibrogammin P in other countries) in patients with congenital FXIII deficiency undergoing surgical procedures. Study Design and Methods FXIII concentrate at preoperative doses ranging from 25 to 40 U/kg was administered to six patients with congenital FXIII deficiency undergoing major or minor surgeries. Results FXIII concentrate was administered immediately before surgery for five surgical cases; three of these patients achieved excellent hemostasis during and after surgery, while two had intraoperative bleeding. In one surgical case, a regular prophylactic dose of FXIII concentrate was administered to the patient 1 week before minor surgery. FXIII concentrate provided rapid replacement of FXIII activity. In all but one of the patients given a dose of FXIII designed to increase FXIII levels more than 50%, there was satisfactory intraoperative and postoperative hemostasis. One patient undergoing aortic valve replacement on cardiopulmonary bypass (CPB) was the exception. Intraoperative bleeding in this patient was associated with lower-than-expected blood levels of FXIII. Conclusion Preoperative plasma-derived FXIII concentrate allowed for sufficient hemostasis in most patients with FXIII deficiencies. Additional doses were necessary to achieve hemostasis in one patient who underwent a CPB procedure.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalTransfusion
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Factor XIII Deficiency
Factor XIII
Hemostasis
Minor Surgical Procedures
Hemorrhage
Cardiopulmonary Bypass
Fibrinolysin
Fibrin
Aortic Valve

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. / Janbain, Maissaa; Nugent, Diane J.; Powell, Jerry S; St-Louis, Jean; Frame, Virginia B.; Leissinger, Cindy A.

In: Transfusion, Vol. 55, No. 1, 01.01.2015, p. 45-50.

Research output: Contribution to journalArticle

Janbain, Maissaa ; Nugent, Diane J. ; Powell, Jerry S ; St-Louis, Jean ; Frame, Virginia B. ; Leissinger, Cindy A. / Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. In: Transfusion. 2015 ; Vol. 55, No. 1. pp. 45-50.
@article{5ed582fa69034fc19f6d70ffd8c8a05a,
title = "Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures",
abstract = "Background Patients with congenital Factor XIII (FXIII) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of FXIII concentrates before and during surgery are lacking. The objective of this study was to report the use of plasma-derived FXIII concentrate (Corifact in the United States; Fibrogammin P in other countries) in patients with congenital FXIII deficiency undergoing surgical procedures. Study Design and Methods FXIII concentrate at preoperative doses ranging from 25 to 40 U/kg was administered to six patients with congenital FXIII deficiency undergoing major or minor surgeries. Results FXIII concentrate was administered immediately before surgery for five surgical cases; three of these patients achieved excellent hemostasis during and after surgery, while two had intraoperative bleeding. In one surgical case, a regular prophylactic dose of FXIII concentrate was administered to the patient 1 week before minor surgery. FXIII concentrate provided rapid replacement of FXIII activity. In all but one of the patients given a dose of FXIII designed to increase FXIII levels more than 50{\%}, there was satisfactory intraoperative and postoperative hemostasis. One patient undergoing aortic valve replacement on cardiopulmonary bypass (CPB) was the exception. Intraoperative bleeding in this patient was associated with lower-than-expected blood levels of FXIII. Conclusion Preoperative plasma-derived FXIII concentrate allowed for sufficient hemostasis in most patients with FXIII deficiencies. Additional doses were necessary to achieve hemostasis in one patient who underwent a CPB procedure.",
author = "Maissaa Janbain and Nugent, {Diane J.} and Powell, {Jerry S} and Jean St-Louis and Frame, {Virginia B.} and Leissinger, {Cindy A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/trf.12784",
language = "English (US)",
volume = "55",
pages = "45--50",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures

AU - Janbain, Maissaa

AU - Nugent, Diane J.

AU - Powell, Jerry S

AU - St-Louis, Jean

AU - Frame, Virginia B.

AU - Leissinger, Cindy A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Patients with congenital Factor XIII (FXIII) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of FXIII concentrates before and during surgery are lacking. The objective of this study was to report the use of plasma-derived FXIII concentrate (Corifact in the United States; Fibrogammin P in other countries) in patients with congenital FXIII deficiency undergoing surgical procedures. Study Design and Methods FXIII concentrate at preoperative doses ranging from 25 to 40 U/kg was administered to six patients with congenital FXIII deficiency undergoing major or minor surgeries. Results FXIII concentrate was administered immediately before surgery for five surgical cases; three of these patients achieved excellent hemostasis during and after surgery, while two had intraoperative bleeding. In one surgical case, a regular prophylactic dose of FXIII concentrate was administered to the patient 1 week before minor surgery. FXIII concentrate provided rapid replacement of FXIII activity. In all but one of the patients given a dose of FXIII designed to increase FXIII levels more than 50%, there was satisfactory intraoperative and postoperative hemostasis. One patient undergoing aortic valve replacement on cardiopulmonary bypass (CPB) was the exception. Intraoperative bleeding in this patient was associated with lower-than-expected blood levels of FXIII. Conclusion Preoperative plasma-derived FXIII concentrate allowed for sufficient hemostasis in most patients with FXIII deficiencies. Additional doses were necessary to achieve hemostasis in one patient who underwent a CPB procedure.

AB - Background Patients with congenital Factor XIII (FXIII) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of FXIII concentrates before and during surgery are lacking. The objective of this study was to report the use of plasma-derived FXIII concentrate (Corifact in the United States; Fibrogammin P in other countries) in patients with congenital FXIII deficiency undergoing surgical procedures. Study Design and Methods FXIII concentrate at preoperative doses ranging from 25 to 40 U/kg was administered to six patients with congenital FXIII deficiency undergoing major or minor surgeries. Results FXIII concentrate was administered immediately before surgery for five surgical cases; three of these patients achieved excellent hemostasis during and after surgery, while two had intraoperative bleeding. In one surgical case, a regular prophylactic dose of FXIII concentrate was administered to the patient 1 week before minor surgery. FXIII concentrate provided rapid replacement of FXIII activity. In all but one of the patients given a dose of FXIII designed to increase FXIII levels more than 50%, there was satisfactory intraoperative and postoperative hemostasis. One patient undergoing aortic valve replacement on cardiopulmonary bypass (CPB) was the exception. Intraoperative bleeding in this patient was associated with lower-than-expected blood levels of FXIII. Conclusion Preoperative plasma-derived FXIII concentrate allowed for sufficient hemostasis in most patients with FXIII deficiencies. Additional doses were necessary to achieve hemostasis in one patient who underwent a CPB procedure.

UR - http://www.scopus.com/inward/record.url?scp=84920872969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920872969&partnerID=8YFLogxK

U2 - 10.1111/trf.12784

DO - 10.1111/trf.12784

M3 - Article

C2 - 25070582

AN - SCOPUS:84920872969

VL - 55

SP - 45

EP - 50

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 1

ER -